PRECISIONBIOLOGICS
Menu
↗
Vendor evaluation

Anti-aging clinic biologics procurement (compliance-first)

Procurement guidance for anti-aging clinics that keeps disease and efficacy claims out of the purchasing file.

Reviewed 2026-10-27

Scope for this care setting

This page covers purchasing and documentation related to anti aging clinic biologics procurement. It does not establish a clinical protocol or a permitted intended use.

Keep outcome marketing and disease claims out of the vendor evaluation. Compare suppliers on documents, logistics, and claim discipline.

Documentation to request and file

Request the current insert, certificate of analysis format, donor eligibility summary approach, sterility testing description, and shipping instructions before the first purchase order.

At receipt, match lot ID, expiration, and shipper condition to the purchase order. Incomplete packs stay open—do not close them by assumption.

Counsel and supervision checkpoints

Physician supervision structures should be documented for account verification. Intended-use questions go to clinic counsel.

Account approval is not authorization for a specific application.

Operations differences that matter

Lyophilized presentations may simplify receiving for clinics without -80°C capacity; cryopreserved presentations typically need dry-ice shipping and qualified freezers.

Confirm the insert for each SKU; do not generalize across brands or sizes.

FAQ

Frequently asked questions

Should price be the first filter?+

No. Filter first on documentation completeness and claim discipline, then compare price.

How many vendors belong on a shortlist?+

Two to three with complete packs is usually enough for a pilot.

What disqualifies a vendor quickly?+

Disease claims, undocumented live-cell promises, or refusal to provide lot-linked documents.

Does this page determine how we may use products discussed under anti aging clinic biologics procurement?+

No. Intended use remains with the ordering physician and clinic counsel.

Sources

  1. FDA: Minimal Manipulation and Homologous Use guidance ↗FDA
  2. 21 CFR Part 1271 ↗eCFR